The invention relates to a pharmaceutical composition comprising: a. 20-75 wt% of a
biodegradable polymer according to Formula (1) POZx, y –(B-R)z (1), wherein POZx, y is a polyoxazoline, B = a
hydrophobic moiety, R = H, or a C1-C18 alkylgroup, x = the number of chain ends of the POZx, y, and is 2, 3, 4, 5 or 6, y = the number of attachment points for B-R at each chain end of the POZx, y, and is 1 or 2, and z is the number of (B-R) groups per
biodegradable polymer, and is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; b. 20-79 wt% of a biocompatible
organic solvent; and c. 1-40 wt% of an active pharmaceutical ingredient; wherein the weight percentages of (a), (b) and (c) are defined relative to the sum of (a)+(b)+(c); wherein the weight fraction of the POZx, y ranges between 4-40 wt% relative to the total weight of the
biodegradable polymer, wherein the weight fraction of the POZx, y is determined by 1H-NMR. The invention also relates to a biodegradable
polymer, and to pharmaceutical compositions comprising the biodegradable
polymer and an active pharmaceutical ingredient, wherein the pharmaceutical compositions are in the form of microparticles, microgranules, microspheres or an
implant.